Disagreements over Duchenne therapy, management style may have led to ouster of key FDA official

What's new in pharma

June 20, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

NIH STAT+ | Disagreements over Duchenne therapy, management style may have led to ouster of key FDA official Nicole Verdun's ouster followed a disagreement over review of cell therapy for Duchenne muscular dystrophy, long-simmering tensions over management style. By Adam Feuerstein, Matthew Herper, Jason Mast, and Lizzy Lawrence STAT+ | What's next for Sarepta Therapeutics with gene therapy under fire? With a tragedy in the news — the death of a second child tied to the therapy — the company faces market consequences, too. By Adam Feuerstein Opinion: Six former CDC vaccine advisory committee chairs warn: U.S. risks losing access to life-saving immunizations We are witnessing a dismantling of the systems that develop, license, recommend, and monitor vaccines, according to vaccine experts. By Grace Lee, Nancy Bennett, Jonathan Temte, Carol Baker, and José Romero Molly Ferguson/STAT STAT+ | Cogent Biosciences-Blueprint Medicines tiff turns spicy on eve of immune drug study readout In this week's edition of "Adam's Biotech Scorecard," Adam looks at drugs for indolent systemic mastocytosis, a common form of an immune system disorder. By Adam Feuerstein

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser